UK-based pharmaceutical giant GlaxoSmithKline has partnered with South San Francisco-based Verily to create Galvani Bioelectronics – a joint venture to develop implantable bioelectric medicines, a branch of medicine that works to fight diseases by targeting electrical signals in the body.
Galvani, owned 55 percent by GSK and 45 percent by Verily (formerly known as Google Life Sciences) will have...
